Indian stocks: Visit www.stage2stocks.com →

Decoy Therapeutics Inc.

Stage 4 · Declining · week 12

As of Oct 22, 2026, Decoy Therapeutics is in Stage 4, the downtrend phase, now in week 12 (since Jul 31, 2026). It closed at $1.03, 97.8% below its 52-week high and below its 200-day average, which is falling.

Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. More about the company

$1.03
-2.23% today
$2.5M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is DCOY early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 30w
S4 41w
S4 16w
S4 48w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 30w → S1 1w → S4 41w → S1 7w → S4 16w → S1 5w → S4 48w → S1 4w → S4 12w current
Total tracked: 166 weeks across 9 stage runs.

DCOY among Biotechnology534th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…534DCOYStage 4 · wk 124−73.2%
vs 52W High
-97.8%
$1.03 lo$47.28 hi
97.8% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 12
1w13w26w
Week 12, established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-82.3%
200 DMA: $5.80 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.01x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-73.2%
3M
-79.6%
6M
-81.0%
YTD
-86.8%
1Y
-97.7%
Scan Membership
Breakout Watch
Latest: 2021-02-05
2 appearances in last 60 days. First seen: 2019-05-22.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 12 · Vol 0.01x
2026-10-21S4
Wk 12 · Vol 0.03x
2026-10-20S4
Wk 12 · Vol 0.01x
2026-10-19S4
Wk 12 · Vol 0.02x
2026-10-16S4
Wk 11 · Vol 0.01x
2026-10-15S4
Wk 11 · Vol 0.03x
2026-10-14S4
Wk 11 · Vol 0.03x
2026-10-13S4
Wk 11 · Vol 0.06x
2026-10-12S4
Wk 11 · Vol 0.02x
2026-10-09S4
Wk 10 · Vol 0.02x
2026-10-08S4
Wk 10 · Vol 0.04x
2026-10-07S4
Wk 10 · Vol 0.03x
Moving averages & range
50 DMA
$2.45
200 DMA
$5.80
52W High
$47.28
52W Low
$1.03
5D Low
$1.03
Resistance levels (recent highs)
20d High
$3.09
60d High
$4.37
120d High
$9.59
250d High
$47.28
Next resistance
+200.0%
to 20d High
P/E (TTM)
0.1
Forward -0.1
ROE
-827.8%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 0.1

Decoy Therapeutics: quick answers

What stage is Decoy Therapeutics in?

As of Oct 22, 2026, Decoy Therapeutics (DCOY) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 31, 2026 and is in week 12. What the four stages mean

Is Decoy Therapeutics in an uptrend?

No. Decoy Therapeutics is in a Stage 4 downtrend. It trades 82.3% below its 200-day average, which is falling.

How far is Decoy Therapeutics from its 52-week high?

Decoy Therapeutics closed at $1.03 on Oct 22, 2026, 97.8% below its 52-week high of $47.28. Its 52-week low is $1.03.

How has Decoy Therapeutics performed over the past year?

As of Oct 22, 2026, Decoy Therapeutics is down 97.7% over the past year and down 86.8% so far in 2026.

Which sector and industry is Decoy Therapeutics in?

Decoy Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting various unmet medical needs. It focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Houston, Texas.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.